An evaluation of emerging vaccines for childhood meningococcal disease

Choudhuri, Debajeet; Huda, Tanvir; Theodoratou, Evropi; Nair, Harish; Zgaga, Lina; Falconer, Rachel; Luksic, Ivana; Johnson, Hope L.; Zhang, Jian Shayne F.; Arifeen, Shams El; Nelson, Christopher B.; Borrow, Ray; Campbell, Harry; Rudan, Igor
January 2011
BMC Public Health;2011 Supplement 3, Vol. 11 Issue Suppl 3, p1
Academic Journal
Background: Meningococcal meningitis is a major cause of disease worldwide, with frequent epidemics particularly affecting an area of sub-Saharan Africa known as the "meningitis belt". Neisseria meningitidis group A (MenA) is responsible for major epidemics in Africa. Recently W-135 has emerged as an important pathogen. Currently, the strategy for control of such outbreaks is emergency use of meningococcal (MC) polysaccharide vaccines, but these have a limited ability to induce herd immunity and elicit an adequate immune response in infant and young children. In recent times initiatives have been taken to introduce meningococcal conjugate vaccine in these African countries. Currently there are two different types of MC conjugate vaccines at late stages of development covering serogroup A and W-135: a multivalent MC conjugate vaccine against serogroup A,C,Y and W-135; and a monovalent conjugate vaccine against serogroup A. We aimed to perform a structured assessment of these emerging meningococcal vaccines as a means of reducing global meningococal disease burden among children under 5 years of age. Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In the first stage we systematically reviewed the literature related to emerging MC vaccines relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). They answered questions from CHNRI framework and their "collective optimism" towards each criterion was documented on a scale from 0 to 100%. Results: For MenA conjugate vaccine the experts showed very high level of optimism (∼90% or more) for 7 out of the 12 criteria. The experts felt that the likelihood of efficacy on meningitis was very high (∼90%). Deliverability, acceptability to health workers, end users and the effect on equity were all seen as highly likely (~90%). In terms of the maximum potential impact on meningitis disease burden, the median potential effectiveness of the vaccines in reduction of overall meningitis mortality was estimated to be 20%; (interquartile range 20-40% and min. 8%, max 50 %). For the multivalent meningococcal vaccines the experts had similar optimism for most of the 12 CHNRI criteria with slightly lower optimism in answerability and low development cost criteria. The main concern was expressed over the cost of product, its affordability and cost of implementation. Conclusions: With increasing recognition of the burden of meningococcal meningitis, especially during epidemics in Africa, it is vitally important that strategies are taken to reduce the morbidity and mortality attributable to this disease. Improved MC vaccines are a promising investment that could substantially contribute to reduction of child meningitis mortality world-wide.


Related Articles

  • Definition and characterization of localised meningitis epidemics in Burkina Faso: a longitudinal retrospective study.  // BMC Infectious Diseases;2012, Vol. 12 Issue 1, p2 

    The article presents a study focusing on definition and characterization of localised meningitis epidemics in Burkina Faso. The study concludes that the definition of localised epidemics at the health centre level is useful for risk factor and modelling studies to understand the meningitis belt...

  • Call for Congo Vaccine. Gopal, Kevin // Pharmaceutical Executive;Nov2001, Vol. 21 Issue 11, p19 

    Reports on the readiness of the World Health Organization (WHO) to supply meningitis vaccines to Congo if the outbreak of the disease warrants it. Reported cases of meningitis in the country as of November 2001; Concerns on the possible spread of the outbreak to Rwanda and the inadequacy of the...

  • Meningococcal disease: Oh no, not another childhood vaccine. Weir, Erica // CMAJ: Canadian Medical Association Journal;4/16/2002, Vol. 166 Issue 8, p1064 

    Focuses on the prevention of meningococcal disease in Canada. Epidemiology and background, including discussion of the role of the pathogen Neisseria meningitidis in causing bacterial meningitis; Clinical management, including discussion of the treatment of meningitis in adults and children...

  • The medical legacy of a promising young fiddle player. Riehl, Winston P. // Cortlandt Forum;Jul2006, Vol. 19 Issue 7, p71 

    The article discusses the decision of the author, a medical doctor, to notify all his patients and friend with children in the susceptible age groups to make sure they are vaccinated against meningitis in the United States. This decision was prompted by the death of a young boy, a violinist, due...

  • Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience.  // Weekly Epidemiological Record;9/16/2005, Vol. 80 Issue 37, p313 

    The article discusses epidemic meningococcal meningitis in Africa. Meningococcal meningitis is a bacterial infection of the meninges, the thin lining that surrounds the brain and spinal cord, whose common symptoms are sudden onset of headache, high fever, stiff neck and sensitivity to light. The...

  • Intercountry meningitis meeting: preparing for the next epidemic seasons, Mali, October 2006.  // Weekly Epidemiological Record;2/2/2007, Vol. 82 Issue 5, p34 

    The article presents information related to a meeting on enhanced surveillance and responses to meningitis epidemics which was held on October 17 to 19, 2006 in Bamako, Mali. The purpose of the meeting was to examine the results of epidemiological and laboratory surveillance. More than 80...

  • Fungal meningitis outbreak kills 36. Talsma, Julia // Drug Topics;Dec2012, Vol. 156 Issue 12, p26 

    The article presents information on outbreak of fungal meningitis in the U.S. The Centers for Disease Control and Prevention (CDC) is stated to be tracking the number of cases and deaths from the outbreak linked to contaminated steroid injections that was prepared by the New England Compounding...

  • Epidemic of Fear. Williams, Daniel // Time International (South Pacific Edition);8/5/2002, Issue 30, p20 

    Reports the death of seven-year-old Rebecca Calverley of New South Wales from Meningococcal disease. Fears of Australians concerning the disease; Comments of Sydney GP Paul Koenig, who said that there is no epidemic in Australia.

  • Meningitis Prompts School Closings In Virginia Town.  // Education Week;4/2/1986, Vol. 5 Issue 28, p3 

    The article reports on the temporary closure of six public schools in Staunton, Virginia. It was decided to close the schools after an outbreak of life-threatening bacterial meningitis cause panic to residents at the Shenandoah Valley town. Seven of the town's children are at risk to brain...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics